GLP-1 Receptor Agonists and Inflammation Reduction

Mechanisms of Action

GLP-1 receptor agonists have well-established anti-inflammatory effects through multiple mechanisms, including reduction of systemic inflammation, decreased platelet aggregation, anti-atherosclerotic properties, and suppression of inflammatory cytokines, as noted by Anaesthesia 1, 2, 3
The cardioprotective effects of GLP-1 receptor agonists are mediated through several anti-inflammatory pathways, including direct anti-inflammatory and anti-atherosclerotic effects that reduce cardiovascular risk independent of glucose control 1, 2
Decreased systemic inflammation and platelet aggregation occur rather than effects on platelet production, as noted by the American Heart Association 3

Improved endothelial function is achieved through anti-inflammatory mechanisms in arterial walls, as reported by Anaesthesia and Praxis Medical Insights 1, 3
Cardiovascular mortality reduction is demonstrated in major trials (LEADER, SUSTAIN 6, SELECT), though these benefits extend beyond anti-inflammatory effects alone, according to Anaesthesia 1, 4
Reduction in epicardial adipose tissue thickness (36% reduction at 6 months with liraglutide) is associated with decreased inflammation and improved cardiac outcomes in patients with obesity and type 2 diabetes, as noted by Praxis Medical Insights 3

The European Association for the Study of the Liver (EASL) recommends GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) as preferred pharmacological options for treating MASLD/MASH without cirrhosis (F0-F3) 3
Reduction of hepatic steatosis and inflammation occurs in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), as reported by Praxis Medical Insights 3
The LEAN trial demonstrated that liraglutide led to more frequent resolution of NASH and less progression of fibrosis compared to placebo, according to Praxis Medical Insights 3

The anti-inflammatory effects are dose-dependent and occur with therapeutic dosing used for diabetes and obesity management, as noted by Anaesthesia 1
Benefits extend to patients without diabetes who have cardiovascular disease and BMI >27, as demonstrated in the SELECT trial, according to Anaesthesia 4
Start at low doses and titrate slowly to minimize gastrointestinal side effects while achieving anti-inflammatory benefits, as advised by the American Gastroenterological Association and Praxis Medical Insights 3
Use with caution in patients with a history of pancreatitis, as recommended by the American Association of Clinical Endocrinologists, though acute pancreatitis remains a rare adverse effect 3, 4

The LEADER trial with liraglutide showed 13% relative risk reduction in cardiovascular death, non-fatal MI, or stroke (13% vs 14.9%, p=0.01) 5
The SUSTAIN 6 trial with semaglutide demonstrated cardiovascular outcomes of 6.6% vs 8.9% (RR 0.74, 95% CI 0.58-0.95) 6
The SELECT trial in non-diabetic patients with cardiovascular disease and BMI >27 showed cardiovascular events of 6.5% vs 8.2% (p=0.001) with semaglutide 2.4 mg weekly 5
The 2024 ESC Guidelines recommend GLP-1 receptor agonists with proven cardiovascular benefit for all patients with type 2 diabetes and chronic coronary syndromes, and should be considered for overweight/obese patients without diabetes (Class I, Level A evidence) 7

The American Association of Clinical Endocrinologists guidelines suggest using GLP-1 receptor agonists with caution in patients with history of pancreatitis, though acute pancreatitis remains a rare adverse effect 5
The American Heart Association recommends avoiding GLP-1 receptor agonists if recent heart failure decompensation 7